Nose to brain delivery of mirtazapine via lipid nanocapsules: Preparation, statistical optimization, radiolabeling, in vivo biodistribution and pharmacokinetic study
Loading...
Files
Date
2024-01
Journal Title
Journal ISSN
Volume Title
Type
Article
Publisher
Springer Publishing Company
Series Info
Drug Delivery and Translational Research;
Scientific Journal Rankings
Abstract
Mirtazapine (MZPc) is an antidepressant drug which is approved by the FDA. It has low bioavailability, which is only 50%, in spite
of its rapid absorption when orally administered owing to high first-pass metabolism. This study was oriented towards delivering
intranasal (IN) mirtazapine by a direct route to the brain by means of preparing lipid nanocapsules (LNCs) as a targeted drug delivery system. MZP-LNCs were constructed by solvent-free phase inversion temperature technique applying D-Optimal mixture design
to study the impact of 3 formulation variables on the characterization of the formulated nanocapsules. Independent variables were
percentage of Labrafac oil, percentage of Solutol and percentage of water. Dependent variables were particle size, polydispersity
index (PDI), Zeta potential and solubilization capacity. Nanocapsules of the optimized formula loaded with MZP were of spherical
shape as confirmed by transmission electron microscopy with particle diameter of 20.59 nm, zeta potential of−5.71, PDI of 0.223
and solubilization capacity of 7.21 mg/g. The in vivo pharmacokinetic behavior of intranasal MZP-LNCs in brain and blood was
correlated to MZP solution after intravenous (IV) and intranasal administration in mice. In vivo biodistribution of the drug in mice
was assessed by a radiolabeling technique using radioiodinated mirtazapine (131I-MZP). Results showed that intranasal MZP-LNCs
were able to deliver higher amount of MZP to the brain with less drug levels in blood when compared to the MZP solution after
IV and IN administration. Moreover, the percentage of drug targeting efficiency (%DTE) of the optimized MZP-LNCs was 332.2
which indicated more effective brain targeting by the intranasal route. It also had a direct transport percentage (%DTP) of 90.68
that revealed a paramount contribution of the nose to brain pathway in the drug delivery to the brain.
Description
Keywords
Mirtazapine · Intranasal · Lipid nanocapsules · Brain · 131I